1. bookVolume 50 (2016): Issue 1 (January 2016)
Journal Details
License
Format
Journal
eISSN
1336-0329
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
access type Open Access

The prepulse inhibition deficit appearance is largely independent on the circadian cycle, body weight, and the gender of vasopressin deficient Brattleboro rat

Published Online: 22 Feb 2016
Volume & Issue: Volume 50 (2016) - Issue 1 (January 2016)
Page range: 16 - 23
Journal Details
License
Format
Journal
eISSN
1336-0329
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
Abstract

Objective. A disturbance of sensorimotor gating measured by prepulse inhibition of acoustic startle (PPI) is one of the best tests of the schizophrenia-like behavior. Vasopressin was implicated in the development of schizophrenia; therefore, the naturally occurring vasopressin-deficient Brattleboro rat has been suggested to be a reliable non-pharmacological animal model. However, previous studies focusing on PPI deficit did not use proper control and despite clear gender differences in the development of the disorder, the effect of gender has been mostly neglected.

Methods. First, we compared the „noise” and „tone” type prepulse at 73-77-81 dB intensity during the light or dark phase using small (~150 g) or big (~500 g) Wistar rats. The test parameters were validated by a pharmacological schizophrenia model (30 mg/kg ketamine i.p.). Than male, female, and lactating vasopressin-deficient animals were compared with +/+ ones.

Results. We established that the prepulse “noise” type is not optimal for PPI testing. The cycle of the day as well as the body weight had no effect on PPI. Even if we compared vasopressin-deficient animals with their closely related +/+ controls, the PPI deficiency was visible with more pronounced effect at 77 dB prepulse intensity similarly to pharmacological schizophrenia model. Despite our expectation, the gender as well as lactation had no effect on the vasopressin-deficiency induced PPI deficit.

Conclusions. The present data confirmed and extended our previous studies that vasopressin-deficient rat is a good model of schizophrenia. It seems that female as well as lactating Brattleboro rats are useful tools for testing putative novel antipsychotics in line with special attention required for schizophrenic women.

Keywords

Adams AL, Hudson A, Ryan CL, Doucette TA. Effects of estrous stage and time of day on prepulse inhibition in female rats. J Neurosci Methods 173, 295–298, 2008.10.1016/j.jneumeth.2008.06.014Search in Google Scholar

Aliczki M, Fodor A, Balogh Z, Haller J, Zelena D. The effects of lactation on impulsive behavior in vasopressin-deficient Brattleboro rats. Horm Behav 66, 545–551, 2014.10.1016/j.yhbeh.2014.08.002Search in Google Scholar

Bakharev VD, Tikhomirov SM, Papsuevich OS, Chipens GI. [Use of vasopressin the treatment of the paranoid form of schizophrenia]. Zh Nevropatol Psikhiatr Im S S Korsakova 84, 88–92, 1984.Search in Google Scholar

Bohus B, de Wied D. The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog Brain Res 119, 555–573, 1998.10.1016/S0079-6123(08)61593-9Search in Google Scholar

Brambilla F, Aguglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R, Catalano M, Drago F. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 15, 114–121, 1986.10.1159/000118253Search in Google Scholar

Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F, Latina A, Picotti GB. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology 20, 113–119, 1989.10.1159/000118483Search in Google Scholar

Caldwell HK, Lee HJ, Macbeth AH, Young WS, 3rd. Vasopressin: behavioral roles of an “original” neuropeptide. Prog Neurobiol 84, 1–24, 2008.10.1016/j.pneurobio.2007.10.007Search in Google Scholar

Chabot CC, Taylor DH. Circadian modulation of the rat acoustic startle response. Behav Neurosci 106, 846–852, 1992.10.1037/0735-7044.106.5.846Search in Google Scholar

Cilia J, Gartlon JE, Shilliam C, Dawson LA, Moore SH, Jones DN. Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J Psychopharmacol 24, 407–419, 2010.10.1177/0269881108098787Search in Google Scholar

da Silva TL, Ravindran AV. Contribution of sex hormones to gender differences in schizophrenia: A review. Asian J Psychiatr 18, 2–14, 2015.10.1016/j.ajp.2015.07.016Search in Google Scholar

Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371, 1624–1632, 2008.10.1016/S0140-6736(08)60695-9Search in Google Scholar

Elman I, Lukas S, Shoaf SE, Rott D, Adler C, Breier A. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J Psychopharmacol 17, 317–323, 2003.10.1177/02698811030173014Search in Google Scholar

Engelmann M, Landgraf R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav 55, 145–149, 1994.10.1016/0031-9384(94)90022-1Search in Google Scholar

Feifel D, Priebe K. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry 50, 425–433, 2001.10.1016/S0006-3223(01)01100-3Search in Google Scholar

Feifel D, Melendez G, Shilling PD. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel anti-psychotic effects. Neuropsychopharmacology 29, 731–738, 2004.10.1038/sj.npp.130037814760394Search in Google Scholar

Feifel D, Priebe K. The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats. J Gen Psychol 134, 173–182, 2007.10.3200/GENP.134.2.172-18217503693Search in Google Scholar

Feifel D, Melendez G, Priebe K, Shilling PD. The effects of chronic administration of established and putative anti-psychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 181, 278–286, 2007.10.1016/j.bbr.2007.04.02017559953Search in Google Scholar

Feifel D, Shilling PD, Melendez G. Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy. J Psychopharmacol 25, 836–841, 2011.10.1177/0269881110388327420971721106605Search in Google Scholar

Fodor A, Barsvari B, Aliczki M, Balogh Z, Zelena D, Goldberg SR, Haller J. The effects of vasopressin deficiency on aggression and impulsiveness in male and female rats. Psychoneuroendocrinology 47, 141–150, 2014.10.1016/j.psyneuen.2014.05.01025001964Search in Google Scholar

Forizs L. Treatment of mental patients with antidiuretic hormone of the posterior pituitary. Dis Nerv Syst 13, 44–47, 1952a.Search in Google Scholar

Forizs L. The use of pitressin in the treatment of schizophrenia with deterioration. N C Med J 13, 76–80, 1952b.Search in Google Scholar

Frankland PW, Ralph MR. Circadian modulation in the rat acoustic startle circuit. Behav Neurosci 109, 43–48, 1995.10.1037/0735-7044.109.1.43Search in Google Scholar

Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S. Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83, 273–277, 1991.10.1111/j.1600-0447.1991.tb05539.x1709331Search in Google Scholar

Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156, 117–154, 2001.10.1007/s002130100811Search in Google Scholar

Goldman MB, Robertson GL, Luchins DJ, Hedeker D, Pandey GN. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 54, 443–449, 1997.10.1001/archpsyc.1997.01830170069010Search in Google Scholar

Golimbet V, Alfimova M, Abramova L, Kaleda V, Gritsenko I. Arginine vasopressin 1a receptor RS3 promoter microsatellites in schizophrenia: a study of the effect of the “risk” allele on clinical symptoms and facial affect recognition. Psychiatry Res 225, 739–740, 2015.10.1016/j.psychres.2014.11.043Search in Google Scholar

Horlington M. Startle response circadian rhythm in rats: lack of correlation with motor activity. Physiol Behav 5, 49–53, 1970.10.1016/0031-9384(70)90012-0Search in Google Scholar

Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol 24, 846–855, 2014.10.1016/j.euroneuro.2014.02.00124636461Search in Google Scholar

Iager AC, Kirch DG, Bigelow LB, Karson CN. Treatment of schizophrenia with a vasopressin analogue. Am J Psychiatry 143, 375–377, 1986.10.1176/ajp.143.3.3753513631Search in Google Scholar

Jiang X, Zhang ZJ, Zhang S, Gamble EH, Jia M, Ursano RJ, Li H. 5-HT2A receptor antagonism by MDL 11,939 during inescapable stress prevents subsequent exaggeration of acoustic startle response and reduced body weight in rats. J Psychopharmacol 25, 289–297, 2011.10.1177/026988110910691119889890Search in Google Scholar

Jobst A, Dehning S, Ruf S, Notz T, Buchheim A, Henning-Fast K, Meissner D, Meyer S, Bondy B, Muller N, Zill P. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr 26, 347–355, 2014.10.1017/neu.2014.2025288094Search in Google Scholar

Kohl S, Heekeren K, Klosterkotter J, Kuhn J. Prepulse inhibition in psychiatric disorders--apart from schizophrenia. J Psychiatr Res 47, 445–452, 2013.10.1016/j.jpsychires.2012.11.01823287742Search in Google Scholar

Korsgaard S, Casey DE, Damgaard Pedersen NE, Jorgensen A, Gerlach J. Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo. Psychopharmacology (Berl) 74, 379–382, 1981.10.1007/BF004327526794086Search in Google Scholar

Kumari V, Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology (Berl) 162, 97–101, 2002.10.1007/s00213-002-1099-xSearch in Google Scholar

Le T, Xia M, Jia M, Sarkar N, Chen J, Li H, Wynn GH, Ursano RJ, Choi KH. Association between initial morphine intake and body weight change, acoustic startle reflex and drug seeking in rats. Psychopharmacology (Berl) 231, 4569–4577, 2014.10.1007/s00213-014-3606-2Search in Google Scholar

Lehmann J, Pryce CR, Feldon J. Sex differences in the acoustic startle response and prepulse inhibition in Wistar rats. Behav Brain Res 104, 113–117, 1999.10.1016/S0166-4328(99)00058-3Search in Google Scholar

Lehtinen EK, Ucar E, Glenthoj BY, Oranje B. Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers. Psychiatry Res 216, 418–423, 2014.10.1016/j.psychres.2014.02.03024613047Search in Google Scholar

Levin R, Heresco-Levy U, Bachner-Melman R, Israel S, Shalev I, Ebstein RP. Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition. Psychoneuroendocrinology 34, 901–908, 2009.10.1016/j.psyneuen.2008.12.01419195791Search in Google Scholar

Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 234, 162–165, 1984.10.1007/BF004615556489403Search in Google Scholar

Mai JK, Berger K, Sofroniew MV. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 34, 133–154, 1993.Search in Google Scholar

Mendrek A. Is It Important to Consider Sex and Gender in Neurocognitive Studies? Front Psychiatry 6, 83, 2015.10.3389/fpsyt.2015.00083445157726082728Search in Google Scholar

Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 51, 395–405, 2007.10.1016/j.yhbeh.2006.12.00717258216Search in Google Scholar

Ohsawa H, Kishimoto T, Shimayoshi N, Matsumura K, Tahara K, Kitera K, Higashiura N, Noriyama Y, Matsumoto H, Hirai M, Ikawa G. Atrial natriuretic peptide and arginine vasopressin secretion in schizophrenic patients. Acta Psychiatr Scand 88, 130–134, 1993.10.1111/j.1600-0447.1993.tb03426.x8213206Search in Google Scholar

Pulliam JV, Dawaghreh AM, Alema-Mensah E, Plotsky PM. Social defeat stress produces prolonged alterations in acoustic startle and body weight gain in male Long Evans rats. J Psychiatr Res 44, 106–111, 2010.10.1016/j.jpsychires.2009.05.005281334419573876Search in Google Scholar

Reilly W, Koirala B, Devaud LL. Sex differences in acoustic startle responses and seizure thresholds between ethanol-withdrawn male and female rats. Alcohol Alcohol 44, 561–566, 2009.10.1093/alcalc/agp049Search in Google Scholar

Robinson GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol 19, e380–e386, 2012.Search in Google Scholar

Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, Pearlson GD, Tamminga CA, Gershon ES, Sweeney JA. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 40, 1374–1384, 2014.10.1093/schbul/sbu027Search in Google Scholar

Seeman MV. Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand 127, 12–22, 2013.10.1111/j.1600-0447.2012.01897.xSearch in Google Scholar

Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D. Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry 60, 1278–1281, 2006.10.1016/j.biopsych.2006.03.045Search in Google Scholar

Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24, 285–301, 1998.10.1093/oxfordjournals.schbul.a033326Search in Google Scholar

Teltsh O, Kanyas-Sarner K, Rigbi A, Greenbaum L, Lerer B, Kohn Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol 15, 309–319, 2012.10.1017/S1461145711001374Search in Google Scholar

Weiss IC, Feldon J, Domeney AM. Circadian time does not modify the prepulse inhibition response or its attenuation by apomorphine. Pharmacol Biochem Behav 64, 501–505, 1999a.10.1016/S0091-3057(99)00100-8Search in Google Scholar

Weiss IC, Feldon J, Domeney AM. Isolation rearing-induced disruption of prepulse inhibition: further evidence for fragility of the response. Behav Pharmacol 10, 139–149, 1999b.10.1097/00008877-199903000-0000310780827Search in Google Scholar

Yang SY, Hong CJ, Huang YH, Tsai SJ. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci Lett 469, 127–130, 2010.10.1016/j.neulet.2009.11.05819944746Search in Google Scholar

Zelena D, Langnaese K, Domokos A, Pinter O, Landgraf R, Makara GB, Engelmann M. Vasopressin administration into the paraventricular nucleus normalizes plasma oxytocin and corticosterone levels in Brattleboro rats. Endocrinology 150, 2791–2798, 2009.10.1210/en.2008-100719246538Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo